Back

Contrast-induced nephropathy following PCI: can we calculate a safe contrast volume?

26 August 2022 (17:15 - 18:00)
Organised by:
Congress Presentation Part of: Revascularisation Revascularisation ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Hugo Costa

Algarve University Hospital Center, Faro (Portugal)

6 More presentations in this session

Presentation thumbnail
Impact of residual coronary lesions on outcomes of myocardial infarction patients with multi-vessel disease
Doctor A. Othman (Assiut, EG)
Abstract Slides
Presentation thumbnail
Procedural and long-term outcomes of stent post dilatation during primary percutaneous coronary interventions
Doctor A. El Amrawy (Alexandria, EG)
Abstract Slides
Presentation thumbnail
Incidence and periprocedural outcomes of heparin-induced thrombocytopenia in on-pump vs off-pump coronary artery bypass grafting patients- analysis from 2016-2019 national inpatient sample
Doctor S. Kambalapalli (Flint, US)
Abstract Slides
Presentation thumbnail
The characteristic of acute coronary syndromes of patients with multivessel coronary artery disease in centers with and without n- cardiac surgery on-site, data from PL-ACS registry.
Doctor K. Brust (Wroclaw, PL)
Abstract Slides
Presentation thumbnail
The 11-year outcome of PCI for treatment of left main stem disease
Doctor K. Khan (Birmingham, GB)
Abstract Slides

Access the full session

Session thumbnail
Revascularisation

The Event

Event poster

ESC Congress 2022

26 August 2022 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Predictors of contrast induced nephropathy in patients with normal renal function undergoing percutaneous coronary intervention - ADAPH score
thumbnail
Congress Presentation
Contrast volume to creatinine clearance ratio, a strong predictor of contrast induced nephropathy in patients undergoing percutaneous intervention
thumbnail
Congress Presentation
Left-digit bias in serum creatinine levels and contrast administration: a nationwide cohort study using a Japanese percutaneous coronary intervention registry

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources